Doorgaan naar hoofdnavigatie
Doorgaan naar zoeken
Ga verder naar hoofdinhoud
Hanze Voorpagina
English
Nederlands
Content zoeken bij Hanze
Voorpagina
Profielen
Onderzoekseenheden
Projecten
Onderzoeksoutput
Datasets
Activiteiten
Knipsels
Prijzen
Topical treatment for facial burns
Cornelis J Hoogewerf
, M Jenda Hop
,
Marianne K Nieuwenhuis
, Irma Mmh Oen
, Esther Middelkoop
, Margriet E Van Baar
Nederlandse Brandwonden Stichting
Martini Ziekenhuis - Brandwondencentrum Groningen
Amsterdam UMC Location Vrije Universiteit, Department of Plastic, Reconstructive and Hand Surgery
Brandwondencentrum Beverwijk - Afdeling Plastisch en Reconstructieve Chirurgie
Onderzoeksoutput
:
Article
›
Academic
›
peer review
Overzicht
Vingerafdruk
Vingerafdruk
Duik in de onderzoeksthema's van 'Topical treatment for facial burns'. Samen vormen ze een unieke vingerafdruk.
Sorteer per
Gewicht
Alfabetische volgorde
Keyphrases
Adverse Effects
16%
Allocation Concealment
8%
Allograft
8%
Antibacterial Agents
8%
Antimicrobial
66%
Aquacel Ag
16%
Bacitracin
8%
Background Pain
8%
Biological Dressings
8%
Burn Care
8%
Burn Center
8%
Burn Injury
16%
Cerium
16%
Certainty Effect
8%
Certainty of Evidence
8%
CINAHL
8%
Clinical Trial Registry
8%
Cochrane
8%
Cochrane Central Register of Controlled Trials
8%
Complete Healing
16%
Confidence Interval
100%
Data Extraction
8%
Deep Partial Thickness Burns
8%
EBSCO
8%
Embase
8%
Enzymatic Debridement
8%
Event Rate
8%
Evidence-based
8%
Expressive Means
8%
Facial Burns
100%
Gentamicin
8%
Grade Estimation
8%
Growth Hormone Treatment
8%
Hazard Ratio
8%
Head-and-neck Region
8%
Health Problems
8%
Health Technology
8%
Helix Aspersa
16%
High Risk
8%
In-process
8%
Infection Risk
8%
Intervention Effect
8%
Length of Hospital Stay
16%
Mafenide Acetate
8%
Means of Communication
8%
MEDLINE
8%
Meta-analysis
8%
Moist Exposed Burn Ointment
50%
Nonbacterial
33%
Ovid
16%
Patient Satisfaction
16%
Person Identity
8%
Porcine
16%
Procedural Pain
8%
Quality Satisfaction
16%
Randomized Controlled Trial
33%
Randomized Methods
8%
Recombinant Human Granulocyte Colony-stimulating Factor (rhG-CSF)
8%
Reduced Time
16%
Review Authors
8%
Risk of Bias
8%
Risk of Bias Assessment
8%
Risk Ratio
33%
Scar Quality
33%
Sequence Generation
8%
Silver Sulfadiazine
41%
Skin Substitute
33%
Sulphadiazine
8%
Superficial Burns
8%
Surgery Pain
8%
Tissue-engineered Skin Substitutes
16%
Topical Agents
8%
Topical Antimicrobials
66%
Topical Intervention
25%
Topical Treatment
100%
Treatment Effect
8%
Wound Area
8%
Wound Healing
41%
Wound Infection
33%
Xenograft
8%
Nursing and Health Professions
Allograft
5%
Antiinfective Agent
100%
Antimicrobial Agent
11%
Artificial Skin
41%
Bacitracin
5%
Biological Dressing
5%
CINAHL
5%
Cochrane Library
5%
Confidence Interval
70%
Cream
23%
Data Extraction
5%
Debridement
5%
Diseases
5%
Embase
5%
Gentamicin
5%
Granulocyte Macrophage Colony Stimulating Factor
5%
Growth Hormone
5%
Hazard Ratio
5%
Hormonal Therapy
5%
Hydrogel
5%
Mafenide Acetate
5%
Meta Analysis
5%
Ointment
35%
Patient Satisfaction
11%
Procedural Pain
5%
Randomization
5%
Steri-Strip
11%
Sulfadiazine
35%
Surface Area
5%
Thermal Burn
100%
Topical Agent
5%
Topical Treatment
100%
Wound
35%
Wound Healing
41%
Wound Infection
23%
Xenograft
5%
Medicine and Dentistry
Adverse Effect
11%
Allograft
5%
Antiinfective Agent
100%
Antimicrobial Agent
11%
Bacitracin
5%
Clinical Trial
5%
Debridement
5%
Diseases
5%
Endocrine Therapy
5%
Gentamicin
5%
Granulocyte Macrophage Colony Stimulating Factor
5%
Growth Hormone
5%
Hazard Ratio
5%
Health Technology
5%
Helix
11%
Mafenide Acetate
5%
Meta-Analysis
5%
Neck
5%
Patient Satisfaction
11%
Primary Outcome
5%
Procedural Pain
5%
Randomized Controlled Trial
23%
Steri-Strip
11%
Sulfadiazine
35%
Thermal Burn
100%
Topical Agent
5%
Topical Treatment
100%
Wound
35%
Wound Healing
41%
Wound Infection
23%
Xenograft
5%
Pharmacology, Toxicology and Pharmaceutical Science
Antiinfective Agent
100%
Antimicrobial Agent
11%
Bacitracin
5%
Burn
100%
Clinical Trial
5%
Diseases
5%
Endocrine Therapy
5%
Gentamicin
5%
Granulocyte Macrophage Colony Stimulating Factor
5%
Growth Hormone
5%
Helix Aspersa
11%
Mafenide Acetate
5%
Procedural Pain
5%
Randomized Controlled Trial
23%
Sulfadiazine
35%
Topical Agent
5%
Wound
35%
Wound Healing
41%
Wound Infection
23%